Adherence: latest news

Adherence resources

  • Drug resistance

    It's important to always take your HIV treatment at the right times and in the right amounts. If you don't, HIV may become drug resistant.When...

    From: The basics

    Information level Level 1
  • HIV and your health

    The outlook has never been better for people with HIV in the UK. With the right HIV treatment and care, most people can expect to have...

    From: Booklets

    Information level Level 2
  • Talking to your doctor

    Taking antiretroviral therapy is a long-term commitment. At present, once you start the drugs, you are likely to be on them for the rest of your life. ...

    From: Booklets

    Information level Level 2
  • Adherence tips

    You may find that a pill box, a phone alarm or a diary helps you with adherence.Adherence can be more challenging when travelling or when...

    From: Factsheets

    Information level Level 2
  • Changing HIV treatment

    Talk to your doctor if you are concerned about any side-effects you are experiencing.If you are having problems taking your HIV treatment, it’s important to be honest...

    From: Factsheets

    Information level Level 2
  • Taking your HIV treatment (adherence)

    Taking your medication exactly as prescribed is key to HIV treatment working.As treatment is a long-term commitment, it’s important that your treatment suits your lifestyle.If you find...

    From: Factsheets

    Information level Level 2
  • Taking drugs on time

    For HIV treatment to work well, you need to always take your pills at the right time, without missing any doses.Taking anti-HIV drugs regularly will...

    From: The basics

    Information level Level 1
  • Your diet and anti-HIV drugs

    Choosing a drug combination that you can fit into your existing eating habits is usually easier than trying to adjust your eating habits to fit the drugs. There...

    From: Booklets

    Information level Level 2
  • Travelling with HIV medications – time zone changes

    Travelling to a new time zone may affect when it’s best to take your medication.If you have an undetectable viral load, taking one dose a few hours...

    From: Factsheets

    Information level Level 2
  • Why taking your HIV treatment properly is so important

    The currently available anti-HIV drugs cannot cure HIV. However, treatment with a combination of these drugs (usually three) can reduce the amount of HIV in your blood (your...

    From: Booklets

    Information level Level 2
  • What does taking your HIV treatment involve?

    Taking your drugs as prescribed is often called ‘adherence’. Adherence to your HIV treatment means: Taking all the medicines that make up your...

    From: Booklets

    Information level Level 2
  • Factors that can affect adherence

    Medicines from the three main classes of anti-HIV drugs (nucleoside reverse transcriptase inhibitors or NRTIs; non-nucleoside reverse transcriptase inhibitors or NNRTIs; and protease inhibitors) are available in forms...

    From: Booklets

    Information level Level 2
  • Taking your HIV treatment

    This booklet provides basic information about how HIV treatment works, what taking it involves and how to manage it in your life....

    From: Booklets

    Information level Level 2
  • Adherence

    Information on adherence to anti-HIV drugs, including advice on how patients can maintain adherence to their therapy and how healthcare providers can help....

    From: HIV treatments directory

    Information level Level 4

Adherence features

Adherence in your own words

Adherence news from aidsmap

More news

Adherence news selected from other sources

  • Adults with HIV who have compassionate care providers start and remain in treatment longer

    Researchers find patients who perceive their primary care providers as lacking empathy and not willing to include them in decision making are at risk for abandoning treatment or not seeking treatment at all.

    15 July 2019 | ScienceDaily
  • Researchers Discuss Ethics and Privacy Concerns About the Growing Field of HIV Adherence Monitoring

    We have several ways to measure adherence to treatment or pre-exposure prophylaxis (PrEP). But as technology changes, and the fields of HIV medicine and public health focus increasingly on monitoring viral suppression or drug concentrations in the body for PrEP, the questions about the ethics of certain technologies, their uses, and what happens to that data are still being debated.

    25 June 2019 | The Body Pro
  • Many Women on HIV Treatment Are at Risk of Developing a Detectable Viral Load

    An ongoing study finds that considerable challenges in such women’s lives may compromise their adherence to antiretrovirals.

    22 May 2019 | Poz
  • NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

    A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.

    09 May 2019 | National Institute of Allergy and Infectious Diseases
  • 'Vast majority' of elevated viral load episodes in pregnant women caused by non-adherence

    Non-adherence to ART — and not pretreatment drug-resistant mutations — explain the “vast majority” of elevated viral load episodes in women initiating ART during pregnancy, according to results from a study conducted in South Africa.

    02 April 2019 | Healio
  • Long-acting injectible antiretroviral trial begins

    Can a monthly injection of two antiretroviral drugs offer a better chance of suppressing the virus than current oral regimens, among individuals with adherence challenges? A trial that will enroll some 350 volunteers with documented lapses in treatment in the preceding year and a half will seek to find out, the National Institutes of Health announced today.

    28 February 2019 | Science Speaks
  • Uganda: Financial incentives do not boost HIV viral suppression rate

    Financial incentives had no effect on viral suppression among HIV-positive adults in Uganda, according to a recent study. Researchers said these findings suggest a need for better interventions to promote the achievement of viral suppression.

    25 January 2019 | Healio
  • Indonesia turns to Global Fund to ensure ARV stock

    Amid rising concerns about the availability of antiretroviral (ARV) therapy drugs following a failed drug tender, the government has given assurances that stocks are enough until the end of this year.

    23 January 2019 | The Jakarta Post
  • What stops people with HIV adhering to long term antiretroviral therapy?

    Long term adherence to antiretroviral therapy (ART) is important in both reducing morbidly and mortality in people living with HIV and reducing transmission rates. A new study published in AIDS Research and Therapy explores people’s reasons for non-adherence to ART through a cohort in Uganda. They find travel, stigma, poor adherence education, and alternative medicine to be prominent factors.

    22 January 2019 | BMC Blogs Network
  • Substance use does not lower adherence to PrEP in MSM

    Study findings showed that substance use does not affect adherence to HIV pre-exposure prophylaxis, or PrEP, among men who have sex with men or transgender women.

    24 November 2018 | Healio
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.